Describes the creation and operation of the initial two heavyweight teams for new drug development and launch. The primary focus is on one of the teams, Evista, although comparisons to the other team, Zyprexa, are included. Lilly must decide the next phas

【書誌情報】

ページ数：24ページ

サイズ：A4

商品番号：HBSP-9-699-016

発行日：1999/3/9

登録日：2007/8/16